Abstract
To the Editor: Myositis-specific autoantibodies (MSAs) were recently reported to be associated with distinctive clinical features of dermatomyositis (DM). For example, anti–transcriptional intermediary factor 1 (TIF1) γ antibody positivity is highly associated with malignancy, and serum anti-MDA5 antibody is a known marker of rapidly progressive interstitial lung disease (ILD).1 To decide treatment approaches for patients with DM, identifying serum MSAs or myositis-associated autoantibodies (MAAs) is quite important, although convenient kits for measuring many kinds of MSAs/MAAs are not always available.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
